Co-Diagnostics Inc
CODX
Company Profile
Business description
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
Contact
2401 S. Foothill Drive
Suite D
Salt Lake CityUT84109
USAT: +1 801 438-1036
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
115
Stocks News & Analysis
stocks
Chart of the Week: China demand for copper falls amidst record rally
Elevated copper prices raise valuation questions.
stocks
Reporting season was stronger than share prices suggest
What 164 ASX earnings results revealed.
stocks
How Anthropic makes money—and what investors should know ahead of its IPO filing
Part one of a two-part Q&A with PitchBook senior analyst Harrison Rolfes on Anthropic’s business model and why it needs to grow margins, fast.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,201.70 | 41.30 | 0.45% |
| CAC 40 | 8,280.63 | 21.22 | -0.26% |
| DAX 40 | 25,839.33 | 130.78 | -0.50% |
| Dow JONES (US) | 53,061.95 | 295.07 | 0.56% |
| FTSE 100 | 10,756.45 | 32.83 | -0.30% |
| HKSE | 25,298.25 | 12.96 | -0.05% |
| NASDAQ | 26,217.83 | 118.05 | 0.45% |
| Nikkei 225 | 64,589.59 | 263.95 | 0.41% |
| NZX 50 Index | 13,915.12 | 15.45 | -0.11% |
| S&P 500 | 7,666.60 | 35.13 | 0.46% |
| S&P/ASX 200 | 9,019.90 | 45.90 | 0.51% |
| SSE Composite Index | 3,958.19 | 16.80 | 0.43% |